KR20050113612A - 인돌리논 화합물을 사용한 과도한 골 용해의 치료 - Google Patents

인돌리논 화합물을 사용한 과도한 골 용해의 치료 Download PDF

Info

Publication number
KR20050113612A
KR20050113612A KR1020057015602A KR20057015602A KR20050113612A KR 20050113612 A KR20050113612 A KR 20050113612A KR 1020057015602 A KR1020057015602 A KR 1020057015602A KR 20057015602 A KR20057015602 A KR 20057015602A KR 20050113612 A KR20050113612 A KR 20050113612A
Authority
KR
South Korea
Prior art keywords
group
alkyl
heteroaryl
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057015602A
Other languages
English (en)
Korean (ko)
Inventor
레슬리 뮤레이
앤-마리 오파렐
틴야 아브람스
Original Assignee
수젠, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수젠, 인크. filed Critical 수젠, 인크.
Publication of KR20050113612A publication Critical patent/KR20050113612A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020057015602A 2003-02-24 2004-02-23 인돌리논 화합물을 사용한 과도한 골 용해의 치료 Withdrawn KR20050113612A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44886103P 2003-02-24 2003-02-24
US60/448,861 2003-02-24
US10/780,917 2004-02-19
US10/780,917 US20040209937A1 (en) 2003-02-24 2004-02-19 Treatment of excessive osteolysis with indolinone compounds

Publications (1)

Publication Number Publication Date
KR20050113612A true KR20050113612A (ko) 2005-12-02

Family

ID=32930497

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057015602A Withdrawn KR20050113612A (ko) 2003-02-24 2004-02-23 인돌리논 화합물을 사용한 과도한 골 용해의 치료

Country Status (11)

Country Link
US (1) US20040209937A1 (cg-RX-API-DMAC7.html)
EP (1) EP1599207A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006518756A (cg-RX-API-DMAC7.html)
KR (1) KR20050113612A (cg-RX-API-DMAC7.html)
AU (1) AU2004216188A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407793A (cg-RX-API-DMAC7.html)
CA (1) CA2516786A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05008961A (cg-RX-API-DMAC7.html)
NZ (1) NZ541825A (cg-RX-API-DMAC7.html)
PL (1) PL378762A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004075775A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
RU2399619C2 (ru) * 2005-09-19 2010-09-20 Пфайзер Продактс Инк. Твердые солевые формы замещенного пирролом 2-индолинона
CN101379400A (zh) * 2005-12-22 2009-03-04 诺华有限公司 可溶性人m-csf受体及其应用
CN101367801B (zh) * 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
EP2318364A2 (en) * 2008-07-02 2011-05-11 Generics [UK] Limited Preparation of 3-pyrrole substituted 2-indolinone derivatives
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・(ユーケー)・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
CN102239163A (zh) * 2008-07-24 2011-11-09 特瓦制药工业有限公司 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
CA2731605A1 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US10898211B2 (en) 2015-01-14 2021-01-26 Crossroads Extremity Systems, Llc Opening and closing wedge osteotomy guide and method
US10292713B2 (en) 2015-01-28 2019-05-21 First Ray, LLC Freeform tri-planar osteotomy guide and method
US10376268B2 (en) 2015-02-19 2019-08-13 First Ray, LLC Indexed tri-planar osteotomy guide and method
CN109311811B (zh) * 2016-06-09 2022-09-09 有机合成药品工业株式会社 4-(哌啶-4-基)吗啉的制备方法
WO2021021640A1 (en) 2019-07-26 2021-02-04 Crossroads Extremity Systems, Llc Bone repositioning guide system and procedure
US11304735B2 (en) 2020-02-19 2022-04-19 Crossroads Extremity Systems, Llc Systems and methods for Lapidus repair of bunions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020751B1 (hr) * 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2005508953A (ja) * 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての3−[4−(置換ヘテロサイクリル)−ピロール−2−イルメチリデン]−2−インドリノン誘導体
AU2003233576A1 (en) * 2002-05-17 2003-12-02 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals

Also Published As

Publication number Publication date
US20040209937A1 (en) 2004-10-21
EP1599207A2 (en) 2005-11-30
AU2004216188A1 (en) 2004-09-10
BRPI0407793A (pt) 2006-02-14
CA2516786A1 (en) 2004-09-10
MXPA05008961A (es) 2005-11-04
WO2004075775A2 (en) 2004-09-10
PL378762A1 (pl) 2006-05-15
WO2004075775A3 (en) 2005-04-14
NZ541825A (en) 2008-11-28
JP2006518756A (ja) 2006-08-17

Similar Documents

Publication Publication Date Title
NL1024779C2 (nl) Gecombineerde toediening van een indolinon met een chemotherapeutisch middel voor celproliferatiestoornissen.
AU2002360314B2 (en) Treatment of acute myeloid leukemia with indolinone compounds
JP5336686B2 (ja) 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
JP5102839B2 (ja) 有糸分裂進行を阻害するための化合物
US20040209937A1 (en) Treatment of excessive osteolysis with indolinone compounds
JP2023541522A (ja) 低分子量タンパク質分解物質及びその適用
EA005996B1 (ru) Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
EA023044B1 (ru) Соединения-ингибиторы сигналинга, опосредуемого рецептором notch
EP4519272A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
JP2003535038A (ja) 蛋白質キナーゼ活性の調節および癌化学療法において用いるための3−ヘテロアリーリデニル−2−インドリノン化合物
US20040266843A1 (en) Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
ZA200506371B (en) Treatment of excessive osteolysis with indolinone compounds
JP2007505859A (ja) イマチニブおよびミドスタウリンでの消化管間質腫瘍の処置
HK1120406A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050823

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid